What is the patient acquisition cost for an oncology centre in India?

no published specialty benchmark exists; see CPQL benchmarks for national average methodology

Why the referral network is the acquisition channel, not the ad budget

Most healthcare marketing frameworks assume a patient searches, clicks, enquires and converts within a fairly short window. Oncology breaks that assumption. A large share of oncology patients arrive at a centre because a referring physician, a diagnostic lab or a first-opinion oncologist directed them there, often after a diagnosis has already been made elsewhere. That means the centre's acquisition economics depend heavily on the strength and breadth of its referral relationships — how many physicians know the centre's capabilities, how quickly a diagnostic lab routes an ambiguous result toward a specialist, and how often the centre shows up in second-opinion conversations. A centre with a weak referral network can spend heavily on paid search and still see limited results, because search captures only the portion of demand that starts with a self-directed query rather than a referral.

What paid acquisition can and can't do here

Paid search and social still play a role, mainly for second-opinion queries and for families researching a centre's facilities, physicians or accreditations after a referral has already pointed them there. What paid acquisition can't reasonably be asked to do in this specialty is replace the referral channel entirely, since the compliance restrictions on outcome and effectiveness claims limit how persuasive a cold paid ad can be relative to a trusted physician recommendation. Budgeting acquisition spend as if it were the primary channel, when referral is doing most of the work, tends to produce a misleadingly high apparent cost per patient relative to the centre's real total acquisition picture.

What a centre should actually measure instead

Given the referral-heavy structure, the more useful metrics for an oncology centre are referral-source tracking (which physicians and labs are sending patients, and how consistently), time from first contact to admission, and payer-mix data, since treatment-course economics depend heavily on whether a patient is self-pay, insured, or covered under a government scheme. A single blended acquisition-cost number, without that referral-source and payer-mix context, understates how the centre's growth actually works.

See CPQL benchmarks across specialties where ICG has agreed figures, the oncology industry page for broader positioning, and the oncology marketing agency page for how ICG structures engagements in this specialty. For the budget-side question rather than the unit-economics question, see oncology marketing cost.

Frequently asked questions

Why can't ICG publish a per-patient acquisition cost for oncology? No agreed CPQL figure exists in ICG's benchmark data for this specialty, and given how referral-mediated oncology acquisition is, a single blended figure would be misleading even if one existed.

Is paid search worth the spend for an oncology centre? It plays a role, mainly for second-opinion and facility-research queries, but it should be budgeted as a supplement to referral-network development rather than as the primary acquisition channel.

What's the single most important metric for an oncology centre's growth team to track? Referral-source consistency — which physicians, labs and centres are sending patients, and whether that flow is growing or shrinking — tends to matter more than any single acquisition-cost figure.

How does payer mix affect acquisition economics for an oncology centre? Payer mix changes the value side of the equation significantly, since a self-pay patient, an insured patient and a government-scheme patient represent very different revenue profiles for the same acquisition effort.

Does referral-network development count as a marketing cost? It's often budgeted separately as business development, but functionally it behaves like the centre's primary acquisition channel and should be measured alongside marketing spend, not apart from it.

Can an oncology centre use patient testimonials to support acquisition marketing? Testimonials framed as evidence of a treatment result cross into restricted territory under the NMC Ethics Code 2026 and should be avoided; centres should focus messaging on facilities, credentials and process instead.

Written by Raman Soni. Reviewed by Abhash Kumar, Co-Founder, Strategy.

Detailed answers